18 Jul StimulusBio
Mimi Healy, Ph.D., CEO
Oct. 7 | 4:45pm | FLW Ballroom G
Houston, Texas
(Private)
StimulusBio revolutionizes the development of cell and gene therapies through innovative product solutions that overcome the most critical barriers to widespread use: manufacturing time and cost. Our scalable technologies leverage biologically-directed surface engineering to drive consistent cellular expansion and streamline complex workflows to more efficiently translate discoveries into clinical solutions. The StimulusBio product pipeline centers around a programmable cellular interface that enables precise nanoscale control over cellular interactions, supporting reproducible outcomes and faster iteration in both research and clinical translation. In addition to development, our business-focused scientists guide companies seeking to commercialize their own technologies through the challenges of transitioning innovations to market. Our team brings deep expertise in business planning, product vision and operational development. By combining solution-driven laboratory innovation with expert market strategy, StimulusBio is committed to ensuring that great science successfully makes the leap from the bench to the bedside.
